Matches in SemOpenAlex for { <https://semopenalex.org/work/W4220958913> ?p ?o ?g. }
- W4220958913 endingPage "3131" @default.
- W4220958913 startingPage "3131" @default.
- W4220958913 abstract "Chronic liver disease (CLD) is a global threat to the human population, with manifestations resulting from alcohol-related liver disease (ALD) and non-alcohol fatty liver disease (NAFLD). NAFLD, if not treated, may progress to non-alcoholic steatohepatitis (NASH). Furthermore, inflammation leads to liver fibrosis, cirrhosis, and hepatocellular carcinoma. Vitexin, a natural flavonoid, has been recently reported for inhibiting NAFLD. It is a lipogenesis inhibitor and activates lipolysis and fatty acid oxidation. In addition, owing to its antioxidant properties, it appeared as a hepatoprotective candidate. However, it exhibits low bioavailability and low efficacy due to its hydrophobic nature. A novel rat model for liver cirrhosis was developed by CCL4/Urethane co-administration. Vitexin encapsulated liposomes were synthesized by the 'thin-film hydration' method. Polyethylene glycol (PEG) was coated on liposomes to enhance stability and stealth effect. The diseased rats were then treated with vitexin and PEGylated vitexin liposomes, administered intravenously and orally. Results ascertained the liposomal encapsulation of vitexin and subsequent PEG coating to be a substantial strategy for treating liver cirrhosis through oral drug delivery." @default.
- W4220958913 created "2022-04-03" @default.
- W4220958913 creator A5004152481 @default.
- W4220958913 creator A5011792535 @default.
- W4220958913 creator A5021209007 @default.
- W4220958913 creator A5024366812 @default.
- W4220958913 creator A5029813082 @default.
- W4220958913 creator A5032043270 @default.
- W4220958913 creator A5051060304 @default.
- W4220958913 creator A5051539968 @default.
- W4220958913 creator A5055879362 @default.
- W4220958913 creator A5062406402 @default.
- W4220958913 creator A5073623854 @default.
- W4220958913 creator A5081006366 @default.
- W4220958913 creator A5083152126 @default.
- W4220958913 date "2022-03-15" @default.
- W4220958913 modified "2023-10-05" @default.
- W4220958913 title "A Novel Sprague-Dawley Rat Model Presents Improved NASH/NAFLD Symptoms with PEG Coated Vitexin Liposomes" @default.
- W4220958913 cites W1195955210 @default.
- W4220958913 cites W1228830179 @default.
- W4220958913 cites W1511242279 @default.
- W4220958913 cites W1650596822 @default.
- W4220958913 cites W1844303090 @default.
- W4220958913 cites W1900842650 @default.
- W4220958913 cites W1964051982 @default.
- W4220958913 cites W1964197945 @default.
- W4220958913 cites W1998346230 @default.
- W4220958913 cites W2010042337 @default.
- W4220958913 cites W2013748224 @default.
- W4220958913 cites W2042253399 @default.
- W4220958913 cites W2045115557 @default.
- W4220958913 cites W2047257800 @default.
- W4220958913 cites W2058209310 @default.
- W4220958913 cites W2058668218 @default.
- W4220958913 cites W2066949938 @default.
- W4220958913 cites W2077396556 @default.
- W4220958913 cites W2082847692 @default.
- W4220958913 cites W2103927657 @default.
- W4220958913 cites W2111215209 @default.
- W4220958913 cites W2115956200 @default.
- W4220958913 cites W2115999849 @default.
- W4220958913 cites W2121674487 @default.
- W4220958913 cites W2167939016 @default.
- W4220958913 cites W2168630917 @default.
- W4220958913 cites W2299956717 @default.
- W4220958913 cites W2343332765 @default.
- W4220958913 cites W2405238112 @default.
- W4220958913 cites W2546046192 @default.
- W4220958913 cites W2604987340 @default.
- W4220958913 cites W2706066070 @default.
- W4220958913 cites W2752393931 @default.
- W4220958913 cites W2767390330 @default.
- W4220958913 cites W2770468492 @default.
- W4220958913 cites W2787852841 @default.
- W4220958913 cites W2807911134 @default.
- W4220958913 cites W2893835498 @default.
- W4220958913 cites W2943723389 @default.
- W4220958913 cites W2970805254 @default.
- W4220958913 cites W2990599165 @default.
- W4220958913 cites W3034822890 @default.
- W4220958913 cites W4210986718 @default.
- W4220958913 cites W4211260107 @default.
- W4220958913 cites W4251656620 @default.
- W4220958913 cites W2396527050 @default.
- W4220958913 cites W2417221219 @default.
- W4220958913 doi "https://doi.org/10.3390/ijms23063131" @default.
- W4220958913 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35328564" @default.
- W4220958913 hasPublicationYear "2022" @default.
- W4220958913 type Work @default.
- W4220958913 citedByCount "4" @default.
- W4220958913 countsByYear W42209589132022 @default.
- W4220958913 countsByYear W42209589132023 @default.
- W4220958913 crossrefType "journal-article" @default.
- W4220958913 hasAuthorship W4220958913A5004152481 @default.
- W4220958913 hasAuthorship W4220958913A5011792535 @default.
- W4220958913 hasAuthorship W4220958913A5021209007 @default.
- W4220958913 hasAuthorship W4220958913A5024366812 @default.
- W4220958913 hasAuthorship W4220958913A5029813082 @default.
- W4220958913 hasAuthorship W4220958913A5032043270 @default.
- W4220958913 hasAuthorship W4220958913A5051060304 @default.
- W4220958913 hasAuthorship W4220958913A5051539968 @default.
- W4220958913 hasAuthorship W4220958913A5055879362 @default.
- W4220958913 hasAuthorship W4220958913A5062406402 @default.
- W4220958913 hasAuthorship W4220958913A5073623854 @default.
- W4220958913 hasAuthorship W4220958913A5081006366 @default.
- W4220958913 hasAuthorship W4220958913A5083152126 @default.
- W4220958913 hasBestOaLocation W42209589131 @default.
- W4220958913 hasConcept C126322002 @default.
- W4220958913 hasConcept C185592680 @default.
- W4220958913 hasConcept C2777075537 @default.
- W4220958913 hasConcept C2777130413 @default.
- W4220958913 hasConcept C2777214474 @default.
- W4220958913 hasConcept C2778004101 @default.
- W4220958913 hasConcept C2778772119 @default.
- W4220958913 hasConcept C2779054382 @default.
- W4220958913 hasConcept C2779102576 @default.
- W4220958913 hasConcept C2779134260 @default.
- W4220958913 hasConcept C2779301978 @default.